- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Proof-of-concept study to enumerate large oncosomes using the RareCyte CTC platform

# Proof-of-concept study to enumerate large oncosomes using the RareCyte CTC platform

Liquid biopsy attention goes to circulating tumor cells and cell-free DNA; this AACR 2024 proof-of-concept poster from CellCarta asks whether large oncosomes — cell-free, CK/EpCAM-positive objects larger than 4 µm — can be counted from the same metastatic breast cancer specimens already drawn for CTC analysis on the RareCyte platform.

Presented by CellCarta.

Read or download to see:

- Large oncosomes could be counted from specimens already collected for CTC analysis, and they outnumbered the CTCs. Objects that were CK/EpCAM positive, nucleus free, CD45 negative and larger than 4 µm with evidence of a membrane at 40X were scored as large oncosomes across 15 patient specimens; LO counts ran higher than CTC counts (Wilcoxon signed rank p=6.10E-5) and the two correlated strongly (Spearman r=0.91, p=8.11E-5).

- HER2 was read on the oncosomes themselves, at a rate that tracked the HER2-positive CTCs. HER2-positive large oncosomes appeared in 8 of 9 (89%) blood smears against a mean fluorescence intensity cutoff of 350, and the proportion of HER2-overexpressing oncosomes correlated with the proportion of HER2-positive CTCs (Spearman r=0.71, p=0.05), a comparison the authors note may be affected by low CTC counts.

- The plasma left over after CTC analysis still supported ERBB2 copy number testing. cfDNA extracted from that plasma was of suitable quality for dPCR, and ERBB2 amplification status was correctly identified for 6 of 7 (85%) patients with available tumor copy number data, though concentrations varied and the lowest reading came from the one sample whose ERBB2 result disagreed.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/6096d779abf0b428b91dbd36b5c562f73344a99c.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/6096d779abf0b428b91dbd36b5c562f73344a99c.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026
### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
[View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) 2026
### Clinical Validation of Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression in Metastatic Prostate Cancer Phenotypes
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026
### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research
[Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026
### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026
### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
[View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026
### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025
### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis
[View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025
### A novel device for buffy coat collection
[View Publication](https://doi.org/10.1080/07366205.2025.2534299) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) CyteFinder 2025
### Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) CyteFinder Cellular and Molecular Life Sciences 2025
### Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) CyteFinder Nature Medicine 2025
### Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/)